Compare · BIIB vs CRDL
BIIB vs CRDL
Side-by-side comparison of Biogen Inc. (BIIB) and Cardiol Therapeutics Inc. (CRDL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and CRDL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $30.41B, about 218.0x CRDL ($139.5M).
- BIIB has been more active in the news (16 items in the past 4 weeks vs 8 for CRDL).
- BIIB has more recent analyst coverage (25 ratings vs 6 for CRDL).
- Company
- Biogen Inc.
- Cardiol Therapeutics Inc.
- Price
- -
- -
- Market cap
- $30.41B
- $139.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 16
- 8
- Recent ratings
- 25
- 6
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, an ultra-pure and high concentration cannabidiol oral formulation for the treatment of in hospitalized COVID-19 patients with a prior history of risk factors for CVD; and has completed phase I clinical trials for the treatment of acute myocarditis and other inflammatory heart disease. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability for the treatment chronic heart failure. In addition, it develops proprietary nanotechnology to enable the distribution of water insoluble drugs within the blood circulation, enhance pharmacokinetics, and facilitate drug accumulation in the failing heart. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Latest BIIB
- Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
- Biogen Appoints Michael J. Parini as Chief Legal Officer
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
- Biogen upgraded by Truist with a new price target
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
Latest CRDL
- SEC Form 6-K filed by Cardiol Therapeutics Inc.
- Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
- SEC Form 6-K filed by Cardiol Therapeutics Inc.
- Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
- SEC Form 6-K filed by Cardiol Therapeutics Inc.
- Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
- SEC Form 6-K filed by Cardiol Therapeutics Inc.
- Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
- SEC Form 6-K filed by Cardiol Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Cardiol Therapeutics Inc.